CNS 2021 infographic: Advancing the care of a pediatric neurotransmitter disorder: Experience with an investigational intraputaminal gene replacement therapy for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency
An overview of 3 clinical trials of an investigational gene therapy for the treatment of AADC is provided in this infographic, distributed at the PTC Therapeutics symposium at CNS 2021
Understand the rationale behind intraputaminal gene replacement therapy for the treatment of AADC deficiency
Learn about the clinical trial experience of an investigational gene replacement therapy for the treatment of AADC deficiency from 3 studies
This symposium was developed and funded by PTC Therapeutics at CNS 2021. It was not part of the official program of CNS 2021.
Eladocagene exuparvovec is an investigational gene therapy product currently being developed by PTC Therapeutics for the treatment of patients with deficiency of a protein called AADC. Eladocagene exuparvovec does not currently have a marketing authorization for the treatment of AADC deficiency.
Register now to unlock the content
Register now to access the content on this page
Already registered?
If not, register below
MED-ALL-AADC-2200021 | March 2022
Sign in or register to access exclusive content on this site
Register here to access the content on the site MED-ALL-CORP-2200029 | December 2022
You are now leaving MEDhub, a website provided by PTC Therapeutics. This link will take you to a website to which our Privacy Statement and our Terms and Conditions do not apply.
We encourage you to read the Privacy Policy and the Terms and Conditions of every website you visit. PTC Therapeutics does not endorse and/or influence the content found on websites not owned/operated by PTC Therapeutics.
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.